$496 Million is the total value of Aquilo Capital Management, LLC's 14 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 28.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | Buy | SPDR SER TR S&P BIOTECHput | $223,900,000 | +189.1% | 2,000,000 | +100.0% | 45.15% | +49.6% |
| DRNA | Buy | DICERNA PHARMACEUTICALS INC | $36,949,000 | +62.5% | 1,454,686 | +17.6% | 7.45% | -15.9% |
| ANAB | Buy | ANAPTYSBIO INC | $35,537,000 | +74.8% | 1,590,733 | +10.5% | 7.17% | -9.6% |
| QURE | Buy | UNIQURE NV | $30,624,000 | +28.6% | 679,620 | +35.4% | 6.18% | -33.5% |
| SPRO | Buy | SPERO THERAPEUTICS INC | $26,290,000 | +79.0% | 1,943,081 | +6.9% | 5.30% | -7.4% |
| BPMC | New | BLUEPRINT MEDICINES CORP | $24,572,000 | – | 315,029 | +100.0% | 4.96% | – |
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS IN | $24,329,000 | +93.7% | 563,291 | +29.0% | 4.91% | +0.2% |
| NGM | Buy | NGM BIOPHARMACEUTICALS INC | $21,619,000 | +67.4% | 1,095,184 | +4.6% | 4.36% | -13.4% |
| RGNX | Buy | REGENXBIO INC | $20,384,000 | +130.4% | 553,453 | +102.6% | 4.11% | +19.2% |
| PIRS | PIERIS PHARMACEUTICALS INC | $17,284,000 | +36.0% | 5,575,530 | 0.0% | 3.48% | -29.7% | |
| PRQR | PROQR THRAPEUTICS N V | $14,602,000 | +10.7% | 2,401,570 | 0.0% | 2.94% | -42.7% | |
| GLPG | GALAPAGOS NVspon adr | $8,727,000 | +0.7% | 44,234 | 0.0% | 1.76% | -47.9% | |
| ARGX | New | ARGENX SEsponsored adr | $8,063,000 | – | 35,800 | +100.0% | 1.63% | – |
| MOR | MORPHOSYS AGsponsored ads | $3,037,000 | +28.9% | 95,898 | 0.0% | 0.61% | -33.3% | |
| MRUS | Exit | MERUS N V | $0 | – | -770,183 | -100.0% | -3.63% | – |
| XENE | Exit | XENON PHARMACEUTICALS INC | $0 | – | -1,499,970 | -100.0% | -6.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
| ARROWHEAD PHARMACEUTICALS INC | 18 | Q3 2023 | 22.1% |
| UNIQURE NV | 18 | Q1 2023 | 10.8% |
| SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
| REGENXBIO INC | 16 | Q3 2023 | 12.6% |
| BLUEPRINT MEDICINES CORP | 15 | Q3 2023 | 17.3% |
| ARGENX SE | 15 | Q3 2023 | 3.7% |
| SPDR S&P BIOTECH ETF TR | 14 | Q4 2022 | 52.1% |
| MERUS N V | 14 | Q3 2023 | 13.0% |
| GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
| SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-03-18 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.